# E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia

> **NCT04411134** · PHASE1 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Cervical Intraepithelial Neoplasia

## Interventions

- **BIOLOGICAL:** E7 TCR

## Key facts

- **NCT ID:** NCT04411134
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-05-28
- **Primary completion:** 2020-07-14
- **Final completion:** 2020-07-14
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Closed based on the lack of perceived clinical activity observed from a different study treating a similar patient population with same study agent.
- **Last updated:** 2020-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04411134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04411134, "E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04411134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*